The trademark application TEZSPIRE was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on March 30, 2021, and it was registered by office on July 7, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations for the treatment of respiratory diseases and disorders, pulmonary diseases and disorders, cardiovascular diseases and disorders, inflammation, inflammatory diseases and disorders, autoimmune diseases and disorders, cancer, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, neurological diseases and disorders and metabolic diseases and disorders.